No Data
No Data
Arrowhead Stock Soars on $825M Sarepta Therapeutics Deal
Oppenheimer Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $215
Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs
Sarepta Therapeutics Announces Leadership Change and Equity Deal
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
No Data
No Data